Market research for novel oncology drug with NGS vs. IHC diagnostic strategy

Client Problems

• A mid size biotech company has a drug targeting a rare cancer mutation and wanted to plan an (ideal) CDx test to accompany the drug launch
   

• They wanted to determine the current usage and future adoption of different molecular diagnostic platforms (single analyte, NGS and liquid biopsy)
   

• Understand the pro’s and con’s of each platform and determine stakeholders (payers and physicians) perceptions

What We Did

• Determined treatment flow and molecular diagnostics buy-in process
   

• Conducted primary market research with stakeholders (oncologists, pathologists, and payers; N=31)
   

• Secondary market research to analyze the market and competition
   

• Mapped the niche and adoption of diagnostic platforms (single analyte, NGS, liquid biopsy) in academic vs commercial laboratories

Our Results And Insight

• Patient flow and diagnostic tests buy-in process
   

• Determined the drivers and barriers for NGS adoption
   

• Current use trends and stakeholder opinions of solid NGS, liquid NGS, and IHC